All In Biotech

NDA 207968 · Novartis

Jadenu Sprinkle

Deferasirox · Oral · Iron Chelator

Accelerated approvalOrphan

Last checked: Nov 20, 2026Latest source record: Jul 23, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

May 18, 2017

Approved uses

6

Original approval plus efficacy supplements

Registered trials

97

15 Phase 3, 2 recruiting

FAERS reports

6,732

0 serious, 1,125 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RENAL FAILURE, HEPATIC FAILURE, and GASTROINTESTINAL HEMORRHAGE Renal Failure JADENU can cause acute renal failure and death, particularly in patients with comorbidities and those who are in the advanced stages of their hematologic disorders. Evaluate baseline renal function prior to starting or increasing JADENU dosing in all patients. JADENU is contraindicated in adult and pediatric patients with eGFR less than 40 mL/min/1.73 m 2 . Measure serum creatinine in duplicate prior to initiation of therapy. Monitor renal function at least monthly. For patients with baseline renal impairment or increased risk of acute renal failure, monitor renal function weekly for the first month, then at least monthly. Reduce the starting dose in patients with preexisting renal disease. During therapy, increase the frequency of monitoring and modify the dose for patients with an increased risk of...

What it is approved for

From the label in effect Dec 11, 2025.

JADENU is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) JADENU is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 ) Limitations of Use: The safety and efficacy of JADENU when administered with other iron chelation therapy have not been established. ( 1.3 ) 1.1 Treatment of Chronic Iron Overload Due to Blood Transfusions (Transfusional Iron Overload) JADENU is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. 1.2 Treatment of Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia Syndromes JADENU is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L. 1.3 Limitations of Use The safety and efficacy of JADENU when administered with other iron chelation therapy have not been established.

Mechanism: JADENU (deferasirox) is an orally active chelator that is selective for iron (as Fe 3+ ). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper, there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • JADENU SPRINKLE · DEFERASIROX 180MG · GRANULE, ORAL · Prescription · TE AB
  • JADENU SPRINKLE · DEFERASIROX 360MG · GRANULE, ORAL · Prescription · TE AB
  • JADENU SPRINKLE · DEFERASIROX 90MG · GRANULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Deferasirox" as an intervention, any sponsor and status, largest first.

All 97 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
FDA's data service returned an error (500). The numbers below may be missing or incomplete.

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20062
20073
200814
200916
201031
201137
201273
201344
201444
2015213
2016518
2017585
2018599
2019658
2020750
2021675
2022757
2023536
2024496
2025368
2026313

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Jadenu Sprinkle (Deferasirox)

2024 spending

$87K

Beneficiaries

n/a

13 claims

Per beneficiary

n/a

$135.21 per unit

View as table
YearSpending
2020$3,843,728
2021$918,738
2022$491,452
2023$555,388
2024$87,492

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 181 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.